KB-1193

Milatuzumab

Background

Milatuzumab, also known as hLL1 or IMMU-115, is a humanized monoclonal antibody that targets a specific epitope of the CD74 molecule expressed on monocytes, macrophages, and B cells. Currently, Milatuzumab is being investigated as an immunotherapeutic candidate for the treatment of multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL).

Specifications

Catalog Number:
KB-1193
Cell Line Name:
Milatuzumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CD74
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ: Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology. 1999, 98: 296-302. 10.1046/j.1365-2567.1999.00868.x. 2.Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM: CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007, 13: 5556s-5563s. 10.1158/1078-0432.CCR-07-1167.
Please enable JavaScript in your browser to complete this form.